Please note that this is a preliminary announcement. Final call conditions are expected to be published on 4 November 2026 and may differ from the information currently available.

The European Partnership for Personalised Medicine (EP PerMed), supported by the European Union under Horizon Europe, has announced its 2027 Joint Transnational Call, Cell and Gene Therapy for Personalised Medicine (CGT4PM2027), with an indicative budget of €33 million.

This call supports innovative, multinational research projects focused on the development and validation of novel cell and gene therapies for personalised medicine.

Projects must address at least one of the following approaches:

• Somatic cell therapies.

• Gene therapies.

• Combined cell and gene therapies.

• Novel biological products, including mRNA, other nucleic acid-based approaches, and extracellular vesicles used for gene-based therapeutic procedures.

All disease areas are eligible. The call encourages interdisciplinary and cross-sector collaborations involving academic researchers, healthcare professionals, industry, patient organisations and other relevant stakeholders.

Call structure: Two-stage application process (pre-proposal and full proposal).

Project duration: Not specified in the call documentation.

Objective: To advance innovative cell and gene therapies for personalised medicine through multinational, interdisciplinary research collaborations that support the development and implementation of personalised healthcare approaches.

• Eligible applicants:

  • Universities, higher education institutions and research institutes.

  • Hospitals, clinical research teams, public health institutions and healthcare organisations.

  • Private for-profit organisations, including SMEs and industry.

  • Private non-profit organisations, including foundations, associations and NGOs.

• Consortium requirements: Applications must involve research groups from several countries. The minimum and maximum number of partners, as well as detailed consortium composition rules, have not yet been specified.

• Geographical eligibility: Funding organisations from 25 countries are participating in the call preparation, including Spain, France, Germany, Italy, Portugal, Canada and Israel, among others. Catalonia and Andalusia are also represented through regional funding organisations. Some funding organisations have not yet confirmed their participation.

• Spanish participation: The Instituto de Salud Carlos III (ISCIII) and the Health Departments of Catalonia and Andalusia are listed among the participating funding organisations.

• National and regional regulations: Each partner must comply with the eligibility conditions established by its respective national or regional funding organisation. Applicants should verify their eligibility with the appropriate funding agency.

• Scientific requirements: Proposals must focus on developing and validating innovative cell and/or gene therapies for personalised medicine, addressing at least one of the approaches identified in the call.

• Interdisciplinary participation: Collaboration between preclinical, clinical, bioinformatics, health data, implementation research, health economics and other relevant disciplines is encouraged.

• Cross-sector collaboration: Participation of companies, regulatory bodies, health technology assessment organisations and patient organisations is encouraged.

• Additional international participation: Researchers based anywhere in the world may participate as self-funded partners in successfully selected projects focused on Type 1 Diabetes through the cooperation framework with Breakthrough T1D, subject to its separate approval process.

• Specific career-stage or experience requirements: Not specified in the call documentation.

• Detailed consortium eligibility rules: Not specified in the call documentation.

In case of interest, please click on 'm'interessa' and we will contact you.